Over the past decade, immune checkpoint inhibitors (ICIs), especially those targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) such as pembrolizumab, nivolumab, and atezolizumab, have found increasing use either as monotherapy or in combination with chemotherapy (chemoimmunotherapy) for both early and advanced NSCLC [1, 2]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.